# A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Source: https://onco.cc/trials/nct07297212/  
OnCo record `nct07297212` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of PM8002, Bevacizumab and Temozolomide in glioma & glioblastoma, run by BioNTech SE, now recruiting.

## Summary

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma is a phase 2 interventional study registered as NCT07297212 by BioNTech SE, with 75 participants planned, started 2026-01-15 and due to reach its primary completion in 2028-01. Interventions recorded: Pumitamig, Bevacizumab and Temozolomide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07297212
- Phase: 2
- Setting: A Phase II, Multi-site, Open-label Trial Evaluating the Safety and Efficacy of Pumitamig and Bevacizumab as Monotherapy and Pumitamig in Combination With Temozolomide in Patients With Recurrent Glioblastoma
- Sponsor: BioNTech SE
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT07297212: https://clinicaltrials.gov/study/NCT07297212

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [PM8002](https://onco.cc/drugs/pm8002/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [BioNTech](https://onco.cc/companies/biontech/), [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct07297212.json